HomeCompareGRPOF vs ABBV

GRPOF vs ABBV: Dividend Comparison 2026

GRPOF yields 263.82% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRPOF wins by $649.46M in total portfolio value
10 years
GRPOF
GRPOF
● Live price
263.82%
Share price
$0.76
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$649.56M
Annual income
$372,102,534.33
Full GRPOF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GRPOF vs ABBV

📍 GRPOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRPOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRPOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRPOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRPOF
Annual income on $10K today (after 15% tax)
$22,424.48/yr
After 10yr DRIP, annual income (after tax)
$316,287,154.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GRPOF beats the other by $316,266,098.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRPOF + ABBV for your $10,000?

GRPOF: 50%ABBV: 50%
100% ABBV50/50100% GRPOF
Portfolio after 10yr
$324.83M
Annual income
$186,063,653.05/yr
Blended yield
57.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GRPOF
No analyst data
Altman Z
1.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRPOF buys
0
ABBV buys
0
No recent congressional trades found for GRPOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRPOFABBV
Forward yield263.82%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$649.56M$102.3K
Annual income after 10y$372,102,534.33$24,771.77
Total dividends collected$620.51M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GRPOF vs ABBV ($10,000, DRIP)

YearGRPOF PortfolioGRPOF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$37,082$26,381.74$11,550$430.00+$25.5KGRPOF
2$131,106$91,428.14$13,472$627.96+$117.6KGRPOF
3$442,387$302,104.50$15,906$926.08+$426.5KGRPOF
4$1,426,052$952,697.46$19,071$1,382.55+$1.41MGRPOF
5$4,396,020$2,870,144.59$23,302$2,095.81+$4.37MGRPOF
6$12,972,576$8,268,834.55$29,150$3,237.93+$12.94MGRPOF
7$36,685,499$22,804,841.95$37,536$5,121.41+$36.65MGRPOF
8$99,524,911$60,271,427.98$50,079$8,338.38+$99.47MGRPOF
9$259,306,336$152,814,680.40$69,753$14,065.80+$259.24MGRPOF
10$649,560,314$372,102,534.33$102,337$24,771.77+$649.46MGRPOF

GRPOF vs ABBV: Complete Analysis 2026

GRPOFStock

Grupo Traxión, S.A.B. de C.V. operates as a transportation and logistics company in Mexico. It operates through three segments: Mobility of Cargo, Logistics and Technology, and Mobility of Personnel. The company offers dry and refrigerated box, hopper, platform, midrange units, intermodal and multimodal, import and export, national distribution, cross border, port, cross dock, and door-to-door freight services; logistics integration services, such as land management, control tower, networks consultancy, eCommerce, consolidated, specialized, door-to-door, land, air, and maritime services; and storage services, including dedicated warehousing, shared warehouses, platform crossings, inventory management, product unloading and loading, finishing and raw materials, exports shipping, inverse logistics, automated and aleatory systems, and collection by radiofrequency and/or voice, as well as copacking and production for exports, such as labeling, product assembling, promotional materials, thermal-forming, and sealing. It also provides warehouse management, transport management, and control tower systems; parcel and courier, collection and home delivery, documents return, parcel tracking, domestic and cross-border shipments, guarantees and shipping insurance, and packing and packaging services; and personnel and student transportation services. In addition, the company offers special services, such as rental of trucks and vans for events; national and international moving services; intermediation services; advertising solutions; technological mobility solutions comprising logistics focused digital platforms and mobile applications. The company was formerly known as Fondo de Transporte México, S.A.P.I. de C.V. and changed its name to Grupo Traxión, S.A.B. de C.V. in September 2017. Grupo Traxión, S.A.B. de C.V. was incorporated in 2011 and is based in Mexico City, Mexico.

Full GRPOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GRPOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRPOF vs SCHDGRPOF vs JEPIGRPOF vs OGRPOF vs KOGRPOF vs MAINGRPOF vs JNJGRPOF vs MRKGRPOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.